Posted in Industry News, Mobile News, News
Biopharmaceutical company Quintiles is looking to establish more UK sites, creating pharmaceutical and clinical jobs, reports pharmatimes.com.
The US company sees the UK as a good place for clinical trials and is hoping to open at least two more Prime Sites to go alongside the one at Queen Mary, University of London. Including two other current sites, Quintiles employs 2,000 people in the UK, a figure set to rise with the planned opening of the new Prime Sites.
Lindy Jones, Quintiles head of global integrated site services, says the UK is of “significant interested to us,” with fifty trials currently being run at the Queen Mary site. Jones believe that the UK “has opened up far more to clinical research” in the past eighteen months, meaning that Quintiles is considering opening “an additional two, maybe three Prime Sites in the UK.”
Looking for a job in the science industry? Start by clicking here, now
Posted in General, News
The biopharmaceutical services provider, Quintiles have announced that it will be investing up to $2m in the Australia-based Prana Biotechnology.
Quintiles has been involved with Prana’s work since the company was established in 1997. However, recently Quintiles has subscribed to Prana’s newly subscribed shares in a bid to help support a planned definitive Phase II study with PBT2 (Prana’s lead compound for Alzheimer’s disease).
Speaking of the investment, a spokesperson from Prana stated the company was “delighted to have secured an organisation of the calibre and influence of Quintiles as a significant shareholder and supporter of Prada’s therapeutic goals”.
Are you looking for a job in science? Click here to search our current science jobs now.